2018 American Transplant Congress » Concurrent Session: Liver: Viral Hepatitis
Date: Monday, June 4, 2018
Time: 2:30pm-4:00pm
Location: Room 602/603/604
Session Type: Concurrent Session
Meeting: 2018 American Transplant Congress
- 2:30pm-2:42pm
Diagnostic Accuracy of Non-Invasive Test of Hepatic Fibrosis in Liver Transplant Recipients
D. Galvez,1 C. Bhati,1 M. Siddiqui,2 C. Schmoyer,2 T. Arshad,2 A. Sharma,1 A. Cotterell,1 K. Yadav,1 T. Reichman,1 M. Levy.1
- 2:42pm-2:54pm
Impact of Direct Acting Antiviral Agents (DAAs) for Hepatitis C Virus (HCV)-Induced Liver Diseases on Registration and Outcome on Waiting List (WL) for Liver Transplant (LT)
C. Antoine,1 C. Jasseron,1 F. Conti,2 S. Dharancy,3 C. Duvoux,4 A. Coilly.5
- 2:54pm-3:06pm
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
A. Bixby, L. Fitzgerald, R. Leek, J. Mellinger, S. Tischer.
- 3:06pm-3:18pm
Private Insurance is Associated with Reduce Access to HCV Therapy after Liver Transplantation
D. Axelrod,1 M. Schnitzler,2 B. Kasiske,3 G. Hess,4 R. Bloom,5 F. Gordon,1 H. Randall,2 K. Lentine.2
- 3:18pm-3:30pm
Direct-Acting Antiviral Therapy Immune-Mediated Graft Dysfunction in Liver Transplant Recipients with Hepatitis C
C. Chan,1 E. Agudelo,2 J. Haydek,3 M. Hoteit,4 M. Laurito,5 J. Norvell,3 T. Schiano,6 N. Terrault,2 E. Verna,5 A. Yang,1 J. Levitsky.1
- 3:30pm-3:42pm
Incidence of Acute Cellular Rejection in Liver Transplant Patients Receiving Direct Acting Antivirals for Hepatitis C Treatment
D. Bley,1 L. Sagardia,1 R. Ford,2 S. Todd.1
- 3:42pm-3:54pm
Making Sense of Hepatitis B Reactivation Risk in Anti-HBc Antibody (Ab) Positive Liver Transplant Recipients
S. Leistman,1 J. Melaragno,1 M. Dokus,2 B. Al-Judaibi,2 T. Babu.3
« View all sessions from the 2018 American Transplant Congress